VenatoRx Pharmaceuticals is discovering and developing novel anti-infectives to treat drug resistant bacterial infections and hard-to-treat viral infections. VenatoRx’s lead product is an injectable beta-lactamase inhibitor (BLI) with potent and selective activity against both serine- and metallo-beta-lactamases. In addition, VenatoRx has a broad pipeline of preclinical programmes including an orally bioavailable broad-spectrum BLI, a novel class of penicillin-binding protein inhibitors and novel antiviral agents.

LocationMalvern, PA
CEOChristopher J. Burns
Partner Shelley Chu